Mezzion Pharma's Udenafil Shows Promise for Fontan-Related Liver Disease

FUEL FALD Study Published in Pediatric Cardiology

Mezzion Pharmaceuticals today announced publication of "The FUEL FALD Study: Effects of Udenafil on Liver Stiffness and Fibrosis after Fonta

HLB Shares Plunge to Daily Limit After FDA Rejects Liver Cancer Drug

HLB shares plunged nearly 30% to their daily limit on the 10th after the U.S. FDA issued a third Complete Response Letter for its liver canc

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology compa

HLB liver cancer drug hits FDA setback again over manufacturing issues

HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration iss

Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy

BACKGROUND Right ventricular failure (RVF) is a major determinant of mortality in pulmonary arterial hypertension (PAH), and hepatic dysfunc

<![CDATA[Assessing Bleeding and Variceal Risk Before Anti-VEGF Therapy in HCC]]>